Chris Rubino

414 total citations
17 papers, 334 citations indexed

About

Chris Rubino is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Chris Rubino has authored 17 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 5 papers in Molecular Biology and 5 papers in Cancer Research. Recurrent topics in Chris Rubino's work include Cancer, Lipids, and Metabolism (5 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers) and Peroxisome Proliferator-Activated Receptors (3 papers). Chris Rubino is often cited by papers focused on Cancer, Lipids, and Metabolism (5 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers) and Peroxisome Proliferator-Activated Receptors (3 papers). Chris Rubino collaborates with scholars based in United States and United Kingdom. Chris Rubino's co-authors include James Baldassarre, Michael W. Dunne, Sailaja Puttagunta, Scott Van Wart, Paul G. Ambrose, Sujata M. Bhavnani, J. Loutit, Alan Forrest, William McCulloch and David E. Geller and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Allergy and Clinical Immunology.

In The Last Decade

Chris Rubino

17 papers receiving 318 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chris Rubino United States 7 150 100 81 74 72 17 334
Yasutaka Nakamura Japan 12 85 0.6× 64 0.6× 95 1.2× 35 0.5× 64 0.9× 64 385
Roopali Sharma United States 7 104 0.7× 15 0.1× 60 0.7× 66 0.9× 69 1.0× 21 367
Takaoki Hirose Japan 12 46 0.3× 43 0.4× 104 1.3× 92 1.2× 141 2.0× 74 457
Nina Pastukh Israel 12 88 0.6× 22 0.2× 83 1.0× 12 0.2× 113 1.6× 23 334
Huang-Shen Lin Taiwan 12 51 0.3× 21 0.2× 41 0.5× 54 0.7× 119 1.7× 21 299
Tilman Lingscheid Germany 10 114 0.8× 20 0.2× 55 0.7× 42 0.6× 71 1.0× 24 279
A. Paul Vastola United States 8 45 0.3× 97 1.0× 83 1.0× 179 2.4× 55 0.8× 8 396
Antoine Andremont France 5 41 0.3× 59 0.6× 19 0.2× 17 0.2× 111 1.5× 11 332
Hari Polenakovik United States 9 110 0.7× 41 0.4× 29 0.4× 40 0.5× 60 0.8× 27 208
André Almeida Portugal 12 67 0.4× 55 0.6× 12 0.1× 19 0.3× 127 1.8× 28 253

Countries citing papers authored by Chris Rubino

Since Specialization
Citations

This map shows the geographic impact of Chris Rubino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Rubino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Rubino more than expected).

Fields of papers citing papers by Chris Rubino

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Rubino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Rubino. The network helps show where Chris Rubino may publish in the future.

Co-authorship network of co-authors of Chris Rubino

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Rubino. A scholar is included among the top collaborators of Chris Rubino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Rubino. Chris Rubino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
3.
Brown, J. Martin, Elizabeth A. Lakota, Shawn D. Flanagan, et al.. (2019). Pharmacokinetic-Pharmacodynamic Analyses of Dose Selection for Rezafungin Prophylaxis Against Invasive Fungal Infections in Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation. 25(3). S358–S359. 2 indexed citations
4.
Han, David, Carlos Fernández-Llatas, Eugene J. Sullivan, et al.. (2016). Single dose pharmacokinetics of C16TR for Inhalation (INS1009) vs treprostinil inhalation solution. PA2398–PA2398. 3 indexed citations
5.
Han, David, Carlos Fernández‐Peña, Eugene J. Sullivan, et al.. (2016). Safety and pharmacokinetics study of a single ascending dose of C16TR for inhalation (INS1009). PA2403–PA2403. 6 indexed citations
6.
O’Farrell, Marie, R. Webster Crowley, Timothy S. Heuer, et al.. (2015). Abstract 2675: Biomarker and PK/PD analyses of first in class FASN inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor patients. Cancer Research. 75(15_Supplement). 2675–2675. 2 indexed citations
7.
Voskoboynik, Mark, Jon Infante, Andrew Brenner, et al.. (2015). 27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination. European Journal of Cancer. 51. S724–S724. 5 indexed citations
8.
Dunne, Michael W., et al.. (2015). Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue. Antimicrobial Agents and Chemotherapy. 59(4). 1849–1855. 179 indexed citations
9.
Brenner, Andrew, Jeffrey R. Infante, Manish R. Patel, et al.. (2015). Abstract A54: First-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 as monotherapy or in combination - final results of dose escalation. Molecular Cancer Therapeutics. 14(12_Supplement_2). A54–A54. 6 indexed citations
10.
Brenner, Andrew, Daniel D. Von Hoff, Jeffrey R. Infante, et al.. (2015). First-in-human investigation of the oral first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.. Journal of Clinical Oncology. 33(15_suppl). TPS2615–TPS2615. 16 indexed citations
11.
Infante, Jon, Manish R. Patel, Andrew Brenner, et al.. (2014). 3LBA Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640. European Journal of Cancer. 50. 195–196. 1 indexed citations
12.
Kearns, Gregory L., Chris Rubino, David C. Griffith, et al.. (2011). 88 Levofloxacin pharmacokinetics (PK) after administration of MP-376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis (CF). Journal of Cystic Fibrosis. 10. S23–S23. 19 indexed citations
13.
Rubino, Chris, Sujata M. Bhavnani, Paul G. Ambrose, Alan Forrest, & J. Loutit. (2009). Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulmonary Pharmacology & Therapeutics. 22(4). 279–285. 72 indexed citations
14.
Ambrose, Paul G., Alison Meagher, Julie Passarell, et al.. (2008). Use of a clinically derived exposure–response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints. Diagnostic Microbiology and Infectious Disease. 63(1). 38–42. 13 indexed citations
15.
16.
Baumgartner, Rudolf A., et al.. (2002). The effect of the distomer, (S)-albuterol, is not through alteration of the pharmacokinetics of (R)-albuterol: A population PK analysis. Journal of Allergy and Clinical Immunology. 109(1). S237–S237. 3 indexed citations
17.
Rubino, Chris, et al.. (1999). GERD in Neonates and Pediatrics: Use of Omeprazole. Journal of Pharmacy Practice. 12(6). 492–503. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yasutaka Nakamura Breakdown of academic impact, for papers by Roopali Sharma Breakdown of academic impact, for papers by Takaoki Hirose Breakdown of academic impact, for papers by Nina Pastukh Breakdown of academic impact, for papers by Huang-Shen Lin Breakdown of academic impact, for papers by Tilman Lingscheid Breakdown of academic impact, for papers by A. Paul Vastola Breakdown of academic impact, for papers by Antoine Andremont Breakdown of academic impact, for papers by Hari Polenakovik Breakdown of academic impact, for papers by André Almeida
Rankless by CCL
2026